CASC
NBIX icon

Coppell Advisory Solutions Corp’s Neurocrine Biosciences NBIX Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-423
Closed -$50.5K – 752
2022
Q4 		$50.5K Buy
+423
New +$49.5K 0.02% 296

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Coppell Advisory Solutions Corp's NBIX Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 423 shares — an estimated $50.5K sold.

Coppell Advisory Solutions Corp first reported a position in NBIX in Q4 2022 and held it in 1 quarter. The position peaked at $50.5K in Q4 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 423 Neurocrine Biosciences shares in Q1 2023, an estimated $50.5K.
  • Coppell Advisory Solutions Corp first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's Neurocrine Biosciences position peaked at $50.5K in Q4 2022.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.